Close

CAMEL

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This gene encodes an autoimmunogenic tumor antigen that belongs to the ESO/LAGE family of cancer-testis antigens. This protein is expressed in a wide array of cancers including melanoma, breast cancer, bladder cancer and prostate cancer. This protein is also expressed in normal testis tissue. An alternative open reading frame product of this gene has been described in PMID:10399963. This alternate protein, termed CAMEL, is a tumor antigen that is recognized by melanoma-specific cytotoxic T-lymphocytes. Alternate splicing results in multiple transcript variants.

Associated Disease
  • Cancer
  • TCR Vector Products

  • TCR Cell Products

  • TCR Viral Particles

Loading...
  • Target Species:
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-C021Z Human anti-CAMEL T cell receptor (2/52), pCDTCR1 Human 2/52 Human aa 19-27 (AAQERRVPR) HLA-DR Lentiviral   Add to Cart   Datasheet
TCR-C022Z Human anti-CAMEL T cell receptor (2/54), pCDTCR1 Human 2/54 Human aa 19-27 (AAQERRVPR) HLA-DR Lentiviral   Add to Cart   Datasheet
TCR-C023Z Human anti-CAMEL T cell receptor (2/12), pCDTCR1 Human 2/12 Human aa 46-65 HLA-DR Lentiviral   Add to Cart   Datasheet
TCR-C024Z Human anti-CAMEL T cell receptor (2/33), pCDTCR1 Human 2/33 Human aa 1-20 HLA-DR Lentiviral   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.